IBRN vs. SURI

Last updated Aug 2, 2026

IBRN (iShares Neuroscience and Healthcare ETF) and SURI (Simplify Propel Opportunities ETF) are both Health & Biotech Equities funds. IBRN is passively managed, while SURI is actively managed. Over the past 3 years, IBRN returned 14.57%/yr vs 9.48%/yr for SURI. Their 0.62 correlation means they have sometimes moved together and sometimes differently. IBRN charges 0.47%/yr vs 2.51%/yr for SURI.

Performance

IBRN vs. SURI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Neuroscience and Healthcare ETF (IBRN) and Simplify Propel Opportunities ETF (SURI). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, IBRN achieves a 13.26% return, which is significantly lower than SURI's 17.49% return.

IBRN

• 1D: -3.24%
• 1M: -6.28%
• 6M: 12.31%
• YTD: 13.26%
• 1Y: 59.23%
• 3Y*: 14.57%
• 5Y*: —
• 10Y*: —
• ALL TIME*: 10.28%

SURI

• 1D: -0.28%
• 1M: 0.44%
• 6M: 18.42%
• YTD: 17.49%
• 1Y: 42.84%
• 3Y*: 9.48%
• 5Y*: —
• 10Y*: —
• ALL TIME*: 7.10%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
IBRN iShares Neuroscience and Healthcare ETF	$83.61K	$123.63K	$97.37K
SURI Simplify Propel Opportunities ETF	$54.58K	$50.12K	$70.73K

IBRN vs. SURI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
IBRN iShares Neuroscience and Healthcare ETF	13.26%	28.49%	-2.78%	-1.61%
SURI Simplify Propel Opportunities ETF	17.49%	28.32%	-13.34%	-2.87%

Correlation

The correlation between IBRN and SURI is 0.51, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.51
Correlation (3Y) Balances recent behavior with more history.	0.61
Correlation (All Time) Calculated using the full available price history since Feb 8, 2023	0.62

The correlation between IBRN and SURI shifts across timeframes, from 0.51 (1 year) to 0.62 (all time), reflecting how their relationship changes across market environments.

IBRN vs. SURI - Sectors Allocation Comparison

Sectors	IBRN	SURI
Healthcare	100.0%	56.3%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	43.8%
Financial Services	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

IBRN vs. SURI — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

IBRN

IBRN Risk / Return Rank: 91
IBRN Sharpe Ratio Rank: 91
IBRN Sortino Ratio Rank: 89
IBRN Omega Ratio Rank: 84
IBRN Calmar Ratio Rank: 96
IBRN Martin Ratio Rank: 93

SURI

SURI Risk / Return Rank: 78
SURI Sharpe Ratio Rank: 80
SURI Sortino Ratio Rank: 77
SURI Omega Ratio Rank: 74
SURI Calmar Ratio Rank: 87
SURI Martin Ratio Rank: 74

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

IBRN vs. SURI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Neuroscience and Healthcare ETF (IBRN) and Simplify Propel Opportunities ETF (SURI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	IBRN	SURI	Difference
Sharpe ratio: Return per unit of total volatility	2.29	1.84	+0.45
Sortino ratio: Return per unit of downside risk	3.10	2.49	+0.60
Omega ratio: Gain probability vs. loss probability	1.36	1.31	+0.05
Calmar ratio: Return relative to maximum drawdown	6.42	3.48	+2.94
Martin ratio: Return relative to average drawdown	16.74	9.25	+7.49

IBRN vs. SURI - Sharpe Ratio Comparison

The current IBRN Sharpe Ratio is 2.29, which is comparable to the SURI Sharpe Ratio of 1.84. The chart below compares the historical Sharpe Ratios of IBRN and SURI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

IBRN vs. SURI - Drawdown Comparison

The maximum IBRN drawdown since its inception was -35.38%, smaller than the maximum SURI drawdown of -47.76%. Use the drawdown chart below to compare losses from any high point for IBRN and SURI.

Drawdown Indicators

	IBRN	SURI	Difference
Max Drawdown Largest peak-to-trough decline	-35.38%	-47.76%	+12.38%
Max Drawdown (1Y) Largest decline over 1 year	-9.15%	-11.78%	+2.63%
Max Drawdown (3Y) Largest decline over 3 years	-35.38%	-47.76%	+12.38%
Current Drawdown Current decline from peak	-9.15%	-8.60%	-0.55%
Average Drawdown Average peak-to-trough decline	-9.59%	-17.08%	+7.49%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.50%	4.42%	-0.92%

Volatility

IBRN vs. SURI - Volatility Comparison

iShares Neuroscience and Healthcare ETF (IBRN) has a higher volatility of 7.68% compared to Simplify Propel Opportunities ETF (SURI) at 4.21%. This indicates that IBRN's price experiences larger fluctuations and is considered to be riskier than SURI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	IBRN	SURI	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.68%	4.21%	+3.47%
Volatility (6M) Calculated over the trailing 6-month period	19.64%	14.44%	+5.20%
Volatility (1Y) Calculated over the trailing 1-year period	25.61%	22.22%	+3.39%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.34%	27.90%	-2.56%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.34%	27.90%	-2.56%

IBRN vs. SURI - Expense Ratio Comparison

IBRN has a 0.47% expense ratio, which is lower than SURI's 2.51% expense ratio.

Dividends

IBRN vs. SURI - Dividend Comparison

IBRN's dividend yield for the trailing twelve months is around 0.87%, less than SURI's 15.08% yield.

Position	TTM	2025	2024	2023
IBRN iShares Neuroscience and Healthcare ETF	0.87%	0.99%	0.40%	0.06%
SURI Simplify Propel Opportunities ETF	15.08%	16.31%	21.41%	14.71%

Frequently Asked Questions

Can I hold both IBRN and SURI in my portfolio?

IBRN and SURI have a correlation of 0.51, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, IBRN or SURI?

IBRN has higher volatility (7.68%) compared to SURI (4.21%). In terms of maximum drawdown, IBRN dropped -35.38% vs SURI's -47.76%.

Which ETF is better, IBRN or SURI?

On 3-year performance, IBRN leads with 14.57% vs 9.48% for SURI. On fees, IBRN is cheaper at 0.47% per year. On volatility, SURI has been the lower-risk option at 4.21%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, IBRN or SURI?

Over the 3-year period, IBRN has performed better with a 14.57% return vs 9.48%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, IBRN or SURI?

IBRN is cheaper with a 0.47% expense ratio, compared with 2.51% for SURI.

Which ETF pays a higher dividend yield, IBRN or SURI?

SURI has the higher dividend yield at 15.08%, compared with 0.87% for IBRN.

What is the main difference between IBRN and SURI?

They also come from different issuers: iShares and Simplify. Their fees differ too: 0.47% for IBRN and 2.51% for SURI.

Which has better risk-adjusted returns?

IBRN currently has the higher Sharpe Ratio (2.29 vs 1.84), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.